StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.70−0.06 (-1.26%)

Close on Nov 17, 2026Market cap $290.66MP/E –Yield –

Kyverna Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Kyverna Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $111.90M, down 18.4% year over year. For fiscal 2025 it was $133.72M, up 18.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$133.72M+18.9%
FY2024Dec 31, 2024$112.47M+125.3%
FY2023Dec 31, 2023$49.92M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$27.02M-11.3%
Q2 FY2026Jun 30, 2026$24.79M-30.8%
Q1 FY2026Mar 31, 2026$30.07M-19.7%
Q4 FY2025Dec 31, 2025$30.01M-10.4%
Q3 FY2025Sep 30, 2025$30.46M+4.3%
Q2 FY2025Jun 30, 2025$35.82M+31.1%
Q1 FY2025Mar 31, 2025$37.43M+66.5%
Q4 FY2024Dec 31, 2024$33.48M+95.1%
Q3 FY2024Sep 30, 2024$29.19M+114.0%
Q2 FY2024Jun 30, 2024$27.32M+162.6%
Q1 FY2024Mar 31, 2024$22.48M+158.0%
Q4 FY2023Dec 31, 2023$17.16M–
Q3 FY2023Sep 30, 2023$13.64M–
Q2 FY2023Jun 30, 2023$10.41M–
Q1 FY2023Mar 31, 2023$8.71M–

More Kyverna Therapeutics figures

See a number that looks wrong?